Related Experiment Video
Updated: May 23, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Exploring the Intersections between Triglyceride-rich Lipoproteins and Acute Coronary Syndrome: A Cross-sectional
Priya Baluni1, Sandesh Sadanand Raut, Prasad Chandrakant Bagare
1Department of General Medicine, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune, Maharashtra, India.
Insights
Triglyceride-rich lipoprotein cholesterol (TRL-C) is linked to acute coronary syndrome (ACS) severity. Higher TRL-C levels correlate with more severe ACS, indicating its potential as a cardiovascular risk marker.
Area of Science:
- Cardiology
- Lipid Metabolism
- Clinical Biochemistry
Background:
- Cardiovascular disease (CVD) is a leading cause of death in South Asia, with acute coronary syndrome (ACS) being a critical manifestation.
- Hyperlipidemia is a key risk factor for ACS, and while traditional markers like LDL-C and HDL-C are known, triglyceride-rich lipoproteins (TRLs) are emerging as significant contributors.
- Delayed clearance of TRL remnants is associated with increased cardiovascular risk.
Purpose of the Study:
- To investigate the association between triglyceride-rich lipoprotein cholesterol (TRL-C) and the severity of acute coronary syndrome (ACS).
- To evaluate TRL-C as a potential marker for cardiovascular risk in ACS patients.
Main Methods:
- A cross-sectional study involving 200 ACS patients was conducted between November 2018 and March 2020.
- TRL-C was calculated using lipid profiles. Patients were categorized into ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA) groups.
- Statistical analyses, including ANOVA and Kruskal-Wallis tests, were employed to assess TRL-C levels across ACS types.
Main Results:
- Average TRL-C levels were significantly higher in STEMI patients (43.68 mg/dL) compared to NSTEMI (31.27 mg/dL) and UA (25.31 mg/dL) (P < 0.0001).
- No significant association was found between TRL-C levels and statin use or prior ACS events.
- TRL-C levels demonstrated a significant correlation with the severity of ACS presentation.
Conclusions:
- TRL-C is significantly associated with ACS severity, with higher levels indicating more severe forms of the condition.
- TRL-C remains a significant predictor of ACS severity even with statin use, suggesting its value beyond traditional lipid profiles.
- Further research is warranted to explore TRL-C's role in recurrent ACS and its therapeutic implications.
Background:
Within 20 years, cardiovascular disease (CVD), which is currently the main cause of death in the Indian subcontinent, is expected to overtake all other causes of death in South Asia. Acute coronary syndrome (ACS), a critical form of CVD, is associated with multiple risk factors including hyperlipidemia. While triglyceride-rich lipoproteins (TRLs) and their remnants are well-studied traditional markers such as low-density lipoprotein (LDL-C) and high-density lipoprotein-cholesterol (HDL-C), new research indicates that they may possibly be important in ACS risk. Delayed removal of CM and very LDL remnants has been linked to increased cardiovascular risk. This study aims to explore the association between TRL-C, a surrogate marker for these atherogenic lipoproteins, and ACS.
Materials And Methods:
Between November 2018 and March 2020, a cross-sectional study was carried out in hospitals at Smt. Sucheta Kriplani Hospital and Lady Hardinge Medical College in New Delhi. The study included 200 patients aged 18 or older, diagnosed with ACS. Data were collected on lipid profiles and cardiac biomarkers from venous blood samples. TRL-C was computed by subtracting LDL-C and HDL-C from total cholesterol. Patients were divided into three groups according to the type of ACS they had ST elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina (UA). Statistical analyses, including ANOVA and Kruskal-Wallis tests, were used to examine associations between TRL-C levels and ACS types.
Results:
The average TRL-C was significantly higher in STEMI patients (43.68 mg/dL) compared to NSTEMI (31.27 mg/dL) and UA (25.31 mg/dL) (P < 0.0001). The study found no significant associations between TRL-C levels and the use of statins or between previous ACS events and the spectrum of current ACS.
Conclusion:
TRL-C is significantly associated with the severity of ACS, with higher levels correlating with more severe forms of the condition. Despite the use of statins, TRL-C levels remained a significant predictor of ACS severity, suggesting that TRL-C could be a valuable marker for assessing cardiovascular risk beyond traditional lipid profiles. Further research is needed to explore the role of TRL-C in recurrent ACS and its potential utility in refining treatment strategies.
Related Concept Videos
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:38Inflammation
01:24Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:31Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...